For the Inventor, By the Inventor

Enter assignee name

Tübingen, Germany

Immatics Biotechnologies Gmbh

Calculating rank

USPTO Granted Patents = 728

% Expired Patents = 19.0

CIPO Patents = 16

EPO Patents = 96

Trademarks = 17

Forward Citations = 5,496

Loading Chart...

Loading Chart...

106 inventors (with patents filed for the assignee):

Toni Weinschenk (604 out of 607 patents)

Jens Fritsche (564 out of 568 patents)

Oliver Schoor (538 out of 541 patents)

4. Harpreet Singh (502 out of 505 patents)

5. Andrea Mahr (348 out of 349 patents)

6. Colette Song (212 out of 213 patents)

7. Daniel Johannes Kowalewski (158 out of 159 patents)

8. Heiko Schuster (152 out of 154 patents)

9. Franziska Hoffgaard (75 out of 76 patents)

10. Steffen Walter (75 out of 79 patents)

11. Chih-Chiang Tsou (74 out of 74 patents)

12. Anita Wiebe (74 out of 74 patents)

13. Hans-Georg Rammensee (67 out of 68 patents)

14. Lea Stevermann (57 out of 57 patents)

15. Claudia Wagner (49 out of 50 patents)

Core Competencies:

Peptide-MHC Binding

T Cell Receptors

Antigen Binding Proteins

Immunotherapy

Cancer Treatments

Peptides

MAGE-A

PRAME

HLA

Tumor Antigens

Colorectal Carcinoma

Hepatocellular Carcinoma

728 patents: Sort by Forward Citations

1. 12570760 - Antigen binding proteins specifically binding PRAME (2026-03-10),

2. 12480958 - METHOD FOR THE CHARACTERIZATION OF PEPTIDE:MHC BINDING POLYPEPTIDES (2025-11-25),

3. 12466878 - PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS (2025-11-11),

4. 12351616 - Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers (2025-07-08),

5. 12318407 - Peptides displayed by HLA for use in immunotherapy against different types of cancers (2025-06-03),

6. 12312412 - MAGEB2 binding constructs (2025-05-27),

7. 12297254 - Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers (2025-05-13),

8. 12297252 - T cell receptors with improved pairing (2025-05-13),

9. 12297245 - Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers (2025-05-13),

10. 12295996 - Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers (2025-05-13),

11. 12295995 - Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers (2025-05-13),

12. 12295994 - Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers (2025-05-13),

13. 12290530 - Peptides displayed by HLA for use in immunotherapy against different types of cancers (2025-05-06),

14. 12285443 - Peptides displayed by HLA for use immunotherapy against different types of cancers (2025-04-29),

15. 12281146 - Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers (2025-04-21),

Company Overview

Immatics Biotechnologies GmbH, based in Tübingen, Germany, specializes in the development of innovative cancer immunotherapies. The company focuses on harnessing the power of the immune system to target and eliminate cancer cells through its advanced technologies in peptide-MHC binding and T cell receptor engineering. Immatics is dedicated to creating effective treatments by utilizing antigen binding proteins and peptides, particularly in relation to tumor-associated antigens like MAGE-A and PRAME, aiming to improve outcomes for cancer patients.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

728 Patents

#1 in Tübingen

#71 in Germany

#1,368 in the World

Tübingen, Germany

Immatics Biotechnologies Gmbh

Forward Citations = 5,496

106 inventors:

Toni Weinschenk (604 out of 607 patents)

Jens Fritsche (564 out of 568 patents)

Oliver Schoor (538 out of 541 patents)

4. Harpreet Singh (502 out of 505 patents)

5. Andrea Mahr (348 out of 349 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Immatics Biotechnologies Gmbh. Retrieved from https://idiyas.com/company/immatics-biotechnologies

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…